Sagar Lonial, MD, FACP

Closing their discussion, the panel highlights unmet needs in the management of relapsed/refractory multiple myeloma and shares clinical pearls for community physicians.

Krina Patel, MD, MSc, presents the case of a 65-year-old woman with relapsed/refractory multiple myeloma, and the panel discusses the optimal sequencing of her treatment regimens.

Drs Krina Patel and Hana Safah explain their impressions of the data on BCMA-directed CAR T-cell therapy for relapsed/refractory multiple myeloma and its potential impact on clinical practice.

Dr Sagar Lonial highlights efficacy and safety data from the KarMMA and CARTITUDE-1 clinical trials.

Hana Safah, MD, presents the case of a 63-year-old woman with relapsed/refractory multiple myeloma receiving treatment with a BCMA-directed CAR T-cell therapy.

Sagar Lonial, MD, FACP, reviews the design and outcomes of the DREAMM-2 and ALGONQUIN studies investigating belantamab mafodotin in the treatment of relapsed/refractory multiple myeloma.

The panel describes the factors they consider when selecting an appropriate BCMA-directed bispecific antibody for a patient with relapsed/refractory multiple myeloma.

Hana Safah, MD, details the prevention and management of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma.

Krina Patel, MD, MSc, explains which patients with relapsed/refractory multiple myeloma she would not treat with CAR T-cell therapy, and the options after disease progression on CAR-T.

A look at BCMA targeting in relapsed/refractory multiple myeloma treatment and the BCMA-directed bispecific antibody teclistamab.

Dr Sagar Lonial presents the case of a 58-year-old man with relapsed/refractory multiple myeloma to the panel for discussion.

Sagar Lonial, MD, FACP, provides an overview of the potential treatment options for patients with relapsed/refractory multiple myeloma.

Sagar Lonial, MD, FACP, provides a look at an upcoming Virtual Tumor Board program on BCMA-directed therapies in relapsed/refractory multiple myeloma treatment.

Sagar Lonial, MD, FACP, discusses the management of heavily pretreated relapsed/refractory multiple myeloma and its future.

An expert in multiple myeloma provides insight on the role of belantamab mafodotin in the treatment of heavily pretreated patients with relapsed/refractory multiple myeloma.

Principal investigator Sagar Lonial, MD, FACP, discusses the DREAMM-2 trial and relapsed/refractory multiple myeloma.

Sagar Lonial, MD, FACP, reviews and comments on the treatment options for patients with triple-class relapsed/refractory multiple myeloma (RRMM).

Sagar Lonial, MD, FACP, summarizes the case of a 72-year-old man with heavily pretreated, triple-class relapsed/refractory multiple myeloma (RRMM).

Sagar Lonial, MD, FACP, presents a case of a 72-year-old man with heavily pretreated relapsed/refractory multiple myeloma and discusses treatment options for patients with this diagnosis who have failed multiple prior lines of therapy.

Sagar Lonial, MD, FACP, summarizes current challenges and his hopes for the future concerning the treatment of multiple myeloma.

Sagar Lonial, MD, FACP, focuses on the treatment of multiple myeloma during the COVID-19 pandemic, discussing the standard of care with anti-CD38 monoclonal antibodies and daratumumab.

Sagar Lonial, MD, FACP, explains the importance of daratumumab/lenalidomide/low-dose dexamethasone (DRd) in several key areas, including progression-free survival versus common standard-of-care regimens in the PEGASUS trial, toxicities, and how active patients fare.

Sagar Lonial, MD, FACP, discusses the efficacy data from the phase 3 MAIA study, as well as the role of daratumumab when treating newly diagnosed patients with multiple myeloma.

Sagar Lonial, MD, FACP, highlights first-line therapies available for transplant-ineligible newly diagnosed multiple myeloma, with special considerations regarding comorbidities.

Sagar Lonial, MD, FACP, summarizes a case concerning a 78-year-old man with multiple myeloma, including initial impressions and prognosis at diagnosis.

Sagar Lonial, MD, FACP, presents a case of a 78-year-old man with multiple myeloma and discusses the many facets of treatment for multiple myeloma in the elderly population.

Sagar Lonial, MD, FACP, explains the 2 main challenges physicians face when they are treating patients with smoldering multiple myeloma.